Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Emergent Technologies, Xencor Enter License Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Emergent Technologies, Xencor Enter License Agreement

Provides exclusive rights to use a TCRm monoclonal antibody against Receptor target NY-ESO1

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Emergent Technologies’ portfolio company, Receptor Logic, has entered into an exclusive License Agreement providing Xencor, Inc. with exclusive worldwide rights to use a T-Cell Receptor Mimic (TCRm) monoclonal antibody against the target NY-ESO1, developed by Receptor Logic, for cancer treatment.

“Our expertise in cancer target identification, when coupled with our development of TCRm monoclonal antibodies to cancer targets, provides a powerful pipeline for immuno-oncology drug development,” said chief scientist William Hildebrand, Ph.D. “By identifying HLA/cancer antigen targets and making TCRm monoclonal antibodies to these targets, we provide industry partners with a steady stream of more personalized cancer therapeutics.”

“This agreement with Xencor reflects the significant value of our platform as we continue to advance into personalized medicine,” said Thomas Harlan, chief executive officer of Receptor Logic and its related company, Pure MHC. “We‘re excited to provide one of our TCRm antibodies to Xencor to assist the company in its cancer therapeutic development efforts.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics